摘要
目的:比较帕利哌酮缓释片与奥氮平对精神分裂症患者的疗效及生活质量的影响。方法:将62例精神分裂症患者,随机分为帕利哌酮缓释片组(31例)和奥氮平组(31例)治疗,疗程12周。分别于治疗前与治疗4、8、12周末,应用阴性与阳性症状量表(PANSS)评定疗效,用副反应量表(TESS)评定治疗过程中出现的不良反应,于治疗前和12周末采用生活质量综合评定问卷(GQOLI-74)评定生活质量。结果:两组均有显著疗效,帕利哌酮缓释片组与奥氮平组均可显著提高生活质量(P均<0.01);两组比较无显著性差异(P>0.05)。帕利哌酮缓释片的主要不良反应是锥体外系反应及嗜睡,奥氮平组在体重增加及血糖升高方面与帕利哌酮缓释片组比较有显著性差异(P<0.01)。结论:帕利哌酮缓释片与奥氮平对精神分裂症疗效好,不良反应少,均可提高患者的生活质量。
Objective:To investigate the efficacy and quality of life in schizophrenic patients treated by Paliperidone extended -release tablet and Olanzapine. nethods:A total of 62 patients with schizophrenia were randomly divided into Paliperidone extended -release tablet group and Olanzapine group for 12 -week treatment. Positive and Negative Symptoms Scale (PANSS) was used to e- valuate the clinical efficacy, Treatment Emergent Symptom Scale (TESS) for side effects and General Quality of Life Inventory (GQO- LI - 74 ) for quality of life. Results : The patients in both groups had significant clinical efficacy, and the two drugs obviously improved the quality of life. There were no significant differences in the efficacy and quality of life ( P 〉 0.05 ) between the two groups. The side effects of Paliperidone extended - release tablet were extra pyramidal reactions and drowsiness , and those of Olanzapine were weightgain and increased blood glucose. Conclusions: Paliperidone extended - release tablet and Olanzapine are similar an the treatment ol schizophrenia with fewer side effects , and they both improve quality of life.
出处
《中国民康医学》
2012年第13期1546-1548,共3页
Medical Journal of Chinese People’s Health
关键词
帕利哌酮缓释片
奥氮平
精神分裂症
生活质量
Paliperidone extended-release tablet
Olanzapine
Schizophrenia
Quality of life